Patent · US Active

Progesterone formulations

US10052386B2 · kind B2 · utility

31Cited by
558References
40Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 18, 2013
Grant dateAug 21, 2018
Priority date—
Expiry dateJun 18, 2033

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Various pharmaceutical formulations are disclosed herein. For example, a pharmaceutical formulation is disclosed comprising ultra-micronized progesterone.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.